Economic evaluation of a pharmacist-led IT-based intervention with simple feedback in reducing rates of clinically important errors in medicines management in general practices (PINCER)

1 Division for Social Research in Medicines and Health, The School of Pharmacy, University of Nottingham, University Park, Nottingham, NG7 2RD, UK 2 Department of Medical Sociology and Health Sciences, Faculty of Medicine and Pharmacy, Vrije Universiteit Brussel, Laarbeeklaan 103 B-1090 Brussel, Belgium 3 Drug Usage & Pharmacy Practice Group, School of Pharmacy & Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester, M13 9PL, UK 4 National Institute of Health and Clinical Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT 5 Research and Evaluation Team, Quality and Governance Directorate, NHS Nottinghamshire County, Birch House, Southwell Road West, Mansfield, Nottinghamshire NG21 0HJ 6 Trent Research Design Service, Division of Primary Care, Tower Building, University Park, Nottingham, NG7 2RD, UK 7 Centre for Population Health Sciences, University of Edinburgh, Teviot Place, Edinburgh, EH8 9AG, UK 8 Division of Primary Care, University of Nottingham Medical School, Queen‟s Medical Centre, Nottingham, NG7 2UH, UK. 9 School of Pharmacy, University of Reading, PO Box 226, Whiteknights, Reading, RG6 6AP, UK 10 Department of Primary Health Care and General Practice, Wellington School of Medicine and Health Sciences, University of Otago, Mein Street, Wellington South, New Zealand 10 Consumers in Research Advisory Group, c/o: Research and Evaluation Team, Quality and Governance Directorate, NHS Nottinghamshire County, Birch House, Southwell Road West, Mansfield, Nottinghamshire NG21 0HJ

[1]  B. Strohmer,et al.  Incidence and predictability of amiodarone-induced thyrotoxicosis and hypothyroidism , 2008, Wiener klinische Wochenschrift.

[2]  J. Rey,et al.  Radioiodine ablation of the thyroid to allow the reintroduction of amiodarone treatment in patients with a prior history of amiodarone-induced thyrotoxicosis. , 2004, The American journal of medicine.

[3]  S. Morant,et al.  Emergency admissions for upper gastrointestinal disease and their relation to NSAID use , 1997, Alimentary pharmacology & therapeutics.

[4]  R. Elliott Is QUM an Efficient Use of Healthcare Resources? , 2008 .

[5]  H. Sørensen,et al.  Outcome of peptic ulcer bleeding among users of traditional non‐steroidal anti‐inflammatory drugs and selective cyclo‐oxygenase‐2 inhibitors , 2006, Alimentary pharmacology & therapeutics.

[6]  D. Symmons,et al.  A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling. , 2006, Health technology assessment.

[7]  T. Brennan,et al.  The nature of adverse events in hospitalized patients. Results of the Harvard Medical Practice Study II. , 1991, The New England journal of medicine.

[8]  Dennis A. Revicki,et al.  Costs of Bipolar Disorder , 2012, PharmacoEconomics.

[9]  L. Sharples,et al.  A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context. , 2006, Health technology assessment.

[10]  Miranda R Andrus,et al.  Use of β-Blockers in Patients with COPD , 2004 .

[11]  H. Collard,et al.  A practical guide for clinicians who treat patients with amiodarone: 2007. , 2007, Heart rhythm.

[12]  Aziz Sheikh,et al.  Protocol for the PINCER trial: a cluster randomised trial comparing the effectiveness of a pharmacist-led IT-based intervention with simple feedback in reducing rates of clinically important errors in medicines management in general practices , 2009, Trials.

[13]  J. Dowie Why cost-effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant. , 2004, Health economics.

[14]  Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. , 2005 .

[15]  D W Bates,et al.  Practical approach to determining costs and frequency of adverse drug events in a health care network. , 2001, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[16]  F. Kapczinski,et al.  Correlation between drug treatment adherence and lithium treatment attitudes and knowledge by bipolar patients , 2007, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[17]  H. Sørensen,et al.  30-Day Mortality After Peptic Ulcer Perforation Among Users of Newer Selective Cox-2 Inhibitors and Traditional NSAIDs: A Population-Based Study , 2006, The American Journal of Gastroenterology.

[18]  J. Schwartz,et al.  Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib. , 2000, Rheumatology.

[19]  C. Haffajee,et al.  Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. , 1984, Annals of internal medicine.

[20]  P. Cullinan,et al.  Amiodarone-associated thyroid dysfunction: risk factors in adults with congenital heart disease. , 1999, Circulation.

[21]  N Hurwitz,et al.  Admissions to Hospital due to Drugs , 1969, British medical journal.

[22]  G. Mooney What else do we want from our health services? , 1994, Social Science & Medicine (1967).

[23]  R. Rosenfeld,et al.  Authority , 2010, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[24]  O. Bugnon,et al.  The Nine-Year Sustained Cost-Containment Impact of Swiss Pilot Physicians-Pharmacists Quality Circles , 2010, The Annals of pharmacotherapy.

[25]  L. Braverman,et al.  The effects of amiodarone on the thyroid. , 2001, Endocrine reviews.

[26]  Magnus Johannesson,et al.  Swedish population health-related quality of life results using the EQ-5D , 2004, Quality of Life Research.

[27]  S. Nurko At what level of hyperkalemia or creatinine elevation should ACE inhibitor therapy be stopped or not started? , 2001, Cleveland Clinic journal of medicine.

[28]  Jan Scott,et al.  Nonadherence with mood stabilizers: prevalence and predictors. , 2002, The Journal of clinical psychiatry.

[29]  Y. Hassan,et al.  Incidence of risk factors for developing hyperkalemia when using ACE inhibitors in cardiovascular diseases , 2009, Pharmacy World & Science.

[30]  A. Egberts,et al.  Preventable hospital admissions related to medication (HARM): cost analysis of the HARM study. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[31]  S B Soumerai,et al.  Principles of educational outreach ('academic detailing') to improve clinical decision making. , 1990, JAMA.

[32]  A. El‐Solh,et al.  Clinical factors associated with hyperkalemia in patients with congestive heart failure 1 , 2005 .

[33]  D. Scott,et al.  Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 years. , 2005, Rheumatology.

[34]  A. Ducharme,et al.  Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the Studies of Left Ventricular Dysfunction (SOLVD) trials. , 2006, American heart journal.

[35]  D. Bates,et al.  Effects of computerized physician order entry and clinical decision support systems on medication safety: a systematic review. , 2003, Archives of internal medicine.

[36]  M. Picot,et al.  Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. , 1997, British journal of rheumatology.

[37]  C. Brunia,et al.  Wait and see. , 2001, International journal of psychophysiology : official journal of the International Organization of Psychophysiology.

[38]  R. Ogilvie,et al.  An educational program in digitalis therapy , 1973 .

[39]  Vahram Ghushchyan,et al.  Mapping the EQ-5D Index from the SF-12: US General Population Preferences in a Nationally Representative Sample , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[40]  David W. Bates,et al.  The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group , 1997 .

[41]  G. Devereux,et al.  Adverse effects of a single dose of (+)-sotalol in patients with mild stable asthma. , 1998, British journal of clinical pharmacology.

[42]  Brian J Lipworth,et al.  Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study , 2011, BMJ : British Medical Journal.

[43]  C. Ohmann,et al.  Time-trends in the epidemiology of peptic ulcer bleeding , 2005, Scandinavian journal of gastroenterology.

[44]  Anthony J Avery,et al.  Incidence and Possible Causes of Prescribing Potentially Hazardous/Contraindicated Drug Combinations in General Practice , 2005, Drug safety.

[45]  D. Georgopoulos,et al.  Influence of pindolol on asthmatics and effect of bronchodilators. , 1986, Respiration; international review of thoracic diseases.

[46]  J. Franklyn,et al.  Clinical review 142: cardiac dysrhythmias and thyroid dysfunction: the hidden menace? , 2002, The Journal of clinical endocrinology and metabolism.

[47]  W. Shen,et al.  Implication of serum concentration monitoring in patients with lithium intoxication , 2004, Psychiatry and clinical neurosciences.

[48]  A. Young,et al.  Lithium in maintenance therapy for bipolar disorder , 2006, Journal of psychopharmacology.

[49]  Shepley Orr,et al.  Does responsibility affect the public's valuation of health care interventions? A relative valuation approach to health care safety. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[50]  Bertram Pitt,et al.  Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) , 1997, The Lancet.

[51]  C. Asche,et al.  Rates of Hospitalizations and Emergency Department Visits in Patients with Asthma and Chronic Obstructive Pulmonary Disease Taking β‐Blockers , 2007, Pharmacotherapy.

[52]  D. Farley,et al.  Surgical Management of Amiodarone-associated Thyrotoxicosis: Mayo Clinic Experience , 2004, World Journal of Surgery.

[53]  V. Pettilä,et al.  Survival and quality of life of patients requiring acute renal replacement therapy , 2005, Intensive Care Medicine.

[54]  R. Ward,et al.  Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. , 1984, American journal of ophthalmology.

[55]  R. Rapanà,et al.  Acute renal failure of medical type in an elderly population. , 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[56]  R. Ogilvie,et al.  Adverse drug reactions during hospitalization. , 1967, Canadian Medical Association journal.

[57]  J. Le Heuzey,et al.  A Short‐Term, Randomized, Double‐Blind, Parallel‐Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study , 2010, Journal of cardiovascular electrophysiology.

[58]  Jonathan M. Teich,et al.  Identifying hospital admissions due to adverse drug events using a computer‐based monitor , 2001, AMIA.

[59]  E. Israel,et al.  Treatment with β blockers in people with COPD , 2011, BMJ : British Medical Journal.

[60]  Gustavo A. Cardenas,et al.  Amiodarone induced thyrotoxicosis: diagnostic and therapeutic strategies. , 2003, Cleveland Clinic journal of medicine.

[61]  A. Sheikh,et al.  A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis , 2012, The Lancet.

[62]  Sigall K. Bell,et al.  Guilty, afraid, and alone--struggling with medical error. , 2007, The New England journal of medicine.

[63]  D. Conen,et al.  Clinical Course and Predictors of Outcome , 2007 .

[64]  C. Bombardier,et al.  The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. , 1998, Arthritis and rheumatism.

[65]  B. Palmer Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. , 2004, The New England journal of medicine.

[66]  David J McLernon,et al.  Systematic Review: Health-State Utilities in Liver Disease: A Systematic Review , 2008, Medical decision making : an international journal of the Society for Medical Decision Making.

[67]  A Rastergar,et al.  A Practical Guide for Medical Teachers. , 2002, Postgraduate medical journal.

[68]  C. Hawkey,et al.  Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors , 2003, Gut.

[69]  W. Encinosa,et al.  The Cost and Incidence of Prescribing Errors Among Privately Insured HIV Patients , 2010, PharmacoEconomics.

[70]  M Sculpher,et al.  Evaluating the cost-effectiveness of interventions designed to increase the utilization of evidence-based guidelines. , 2000, Family practice.

[71]  P. Laurberg,et al.  Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and in Jutland, Denmark. , 1998, The Journal of clinical endocrinology and metabolism.

[72]  G. Daniels Amiodarone-induced thyrotoxicosis. , 2001, The Journal of clinical endocrinology and metabolism.

[73]  D. Macpherson,et al.  Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors. How much should we worry? , 1998, Archives of internal medicine.

[74]  N. Maniadakis,et al.  Health-related quality of life measurement in patients admitted with coronary heart disease and heart failure to a cardiology department of a secondary urban hospital in Greece. , 2008, Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese.

[75]  M Sculpher,et al.  A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. , 2004, Health technology assessment.

[76]  A. Pinchera,et al.  Proportion of type 1 and type 2 amiodarone‐induced thyrotoxicosis has changed over a 27‐year period in Italy , 2007, Clinical endocrinology.

[77]  B. Lipworth,et al.  Response to salbutamol in patients with mild asthma treated with nadolol , 2010, European Respiratory Journal.

[78]  A. Weetman,et al.  Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy , 1998, Heart.

[79]  I. Klein,et al.  Thyroid hormone and the cardiovascular system. , 1997, The New England journal of medicine.

[80]  David Lester,et al.  Suicide risk in depression and bipolar disorder: Do impulsiveness-aggressiveness and pharmacotherapy predict suicidal intent? , 2008, Neuropsychiatric disease and treatment.

[81]  Rainu Kaushal,et al.  Analysis of Medication-Related Malpractice Claims: Causes, Preventability, and Costs , 2003 .

[82]  P. Blakely,et al.  A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers , 2009, Therapeutics and clinical risk management.

[83]  C. Isles,et al.  Potassium disorders--clinical spectrum and emergency management. , 2006, Resuscitation.

[84]  A. Gray Adverse events and the National Health Service : an economic perspective a report to the National Patient Safety Agency , 2005 .

[85]  A. B. Hall,et al.  The sequencing of medication administration in the management of hyperkalemia. , 2009, Journal of emergency nursing: JEN : official publication of the Emergency Department Nurses Association.

[86]  D. Goldfarb,et al.  Indications for hospitalization of patients with hyperkalemia. , 2000, Archives of internal medicine.

[87]  Matthew Labreche,et al.  Anticoagulation-associated adverse drug events. , 2011, The American journal of medicine.

[88]  Amanda J Lee,et al.  Characterisation and comparison of health-related quality of life for patients with renal failure , 2005, Current medical research and opinion.

[89]  H. Fabel,et al.  [Changes in lung function following administration of eyedrops containing timolol, metipranolol, pindolol and pilocarpine in healthy probands and patients with mild bronchial asthma]. , 1987, Klinische Wochenschrift.

[90]  K. Harjai,et al.  Effects of Amiodarone on Thyroid Function , 1997, Annals of Internal Medicine.

[91]  A. Berghöfer,et al.  Non-adherence with long-term prophylaxis: a 6-year naturalistic follow-up study of affectively ill patients , 1999, Psychiatry Research.

[92]  S. K. Narayana,et al.  Management of amiodarone-related thyroid problems , 2011, Therapeutic advances in endocrinology and metabolism.

[93]  P. Donnan,et al.  Prescribing of β-adrenoceptor antagonists in asthma: an observational study , 2011, Thorax.

[94]  A. Majeed,et al.  Routinely recorded patient safety events in primary care: a literature review. , 2012, Family practice.

[95]  G. Dunn,et al.  A systematic review and economic model of the clinical effectiveness and cost-effectiveness of interventions for preventing relapse in people with bipolar disorder. , 2007, Health technology assessment.

[96]  D. Symmons,et al.  Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population? , 2006, Rheumatology.

[97]  B. Palmer Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[98]  Sang-Woong Han,et al.  Therapeutic Approach to Hyperkalemia , 2002, Nephron.

[99]  R. Warburton,et al.  Patient safety--how much is enough? , 2005, Health policy.

[100]  R. Baldessarini,et al.  Long-term lithium treatment in the prevention of suicidal behavior in bipolar disorder patients , 2009, Epidemiologia e Psichiatria Sociale.

[101]  J. Franklyn,et al.  Mortality after the treatment of hyperthyroidism with radioactive iodine. , 1998, The New England journal of medicine.

[102]  D. Bates,et al.  The Costs of Adverse Drug Events in Hospitalized Patients , 1997 .

[103]  E. Ziegel,et al.  Root Cause Analysis , 2010, Journal of Clinical Engineering.

[104]  D. Conen,et al.  Amiodarone-induced thyrotoxicosis: clinical course and predictors of outcome. , 2007, Journal of the American College of Cardiology.

[105]  Guy Goodwin,et al.  Recurrence of Mania after Lithium Withdrawal , 1994, British Journal of Psychiatry.

[106]  R. Chadda,et al.  Therapeutic Drug Monitoring of Lithium in Patients With Bipolar Affective Disorder: Experiences From a Tertiary Care Hospital in India , 2009, American Journal of Therapeutics.

[107]  F. Bogazzi,et al.  Approach to the patient with amiodarone-induced thyrotoxicosis. , 2010, The Journal of clinical endocrinology and metabolism.

[108]  Jim Smith,et al.  Building a safer NHS for patients: improving medication safety , 2004 .

[109]  A. Berghöfer,et al.  The Impact of Lithium Long-Term Medication on Suicidal Behavior and Mortality of Bipolar Patients , 2005, Archives of suicide research : official journal of the International Academy for Suicide Research.

[110]  M. Buxton,et al.  Utility loss and indirect costs following cardiovascular events in hypertensive patients: the ASCOT health economic substudy , 2007, The European Journal of Health Economics.

[111]  J. Reason Human error: models and management , 2000, BMJ : British Medical Journal.

[112]  S. Thompson,et al.  Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. , 2000, Statistics in medicine.

[113]  N. Pannu,et al.  Methodological considerations for observational studies of acute kidney injury using existing data sources. , 2009, Journal of nephrology.

[114]  E. Vieta,et al.  Evolving trends in the long-term treatment of bipolar disorder , 2007, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[115]  D. Malatjalian,et al.  Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. , 1996, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[116]  D. Suh,et al.  Clinical and Economic Impact of Adverse Drug Reactions in Hospitalized Patients , 2000, The Annals of pharmacotherapy.

[117]  L. Steuten,et al.  Economic evaluation of healthcare safety: which attributes of safety do healthcare professionals consider most important in resource allocation decisions? , 2010, Quality and Safety in Health Care.

[118]  R. Rodriguez-Monguio,et al.  Assessing the Economic Impact of Adverse Drug Effects , 2012, PharmacoEconomics.

[119]  M. Gossop,et al.  Economic analysis of costs and consequences of the treatment of drug misuse: 2-year outcome data from the National Treatment Outcome Research Study (NTORS). , 2004, Addiction.

[120]  C. Barbosa,et al.  Methodological assessment of economic evaluations of alcohol treatment: what is missing? , 2010, Alcohol and alcoholism.

[121]  P. Ladenson,et al.  Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. , 1995, JAMA.

[122]  S. Srinathan,et al.  Methotrexate: prescribing and monitoring practices among the consultant membership of the British Association of Dermatologists , 2008, The British journal of dermatology.

[123]  P. Laurberg,et al.  Low incidence rate of overt hypothyroidism compared with hyperthyroidism in an area with moderately low iodine intake. , 1999, Thyroid : official journal of the American Thyroid Association.

[124]  A. O’Sullivan,et al.  Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. , 2006, European journal of endocrinology.

[125]  A. Sheikh,et al.  PINCER trial: a cluster randomised trial comparing the effectiveness and cost-effectiveness of a pharmacist-led IT-based intervention with simple feedback in reducing rates of clinically important errors in medicines management in general practices , 2010 .

[126]  D. Classen,et al.  Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. , 1997, JAMA.

[127]  H. Krumholz,et al.  Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. , 2001, Journal of the American College of Cardiology.

[128]  Andrew H. Briggs,et al.  Development of an Economic Model to Assess the Cost Effectiveness of Asthma Management Strategies , 2012, PharmacoEconomics.

[129]  J. Franklyn,et al.  Subclinical hypothyroidism and the risk of coronary heart disease and mortality. , 2010, JAMA.

[130]  A. El‐Solh,et al.  Clinical factors associated with hyperkalemia in patients with congestive heart failure. , 2005, Journal of clinical pharmacy and therapeutics.

[131]  D. Bates,et al.  Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general care units. , 1997, Critical care medicine.

[132]  F. Gobel,et al.  Effect of propranolol on respiratory function and exercise tolerance in patients with chronic obstructive lung disease. , 1975, Chest.

[133]  R. Harris,et al.  Potential side effects of renin inhibitors – mechanisms based on comparison with other renin–angiotensin blockers , 2006, Expert opinion on drug safety.

[134]  M. Sculpher,et al.  Representing uncertainty: the role of cost-effectiveness acceptability curves. , 2001, Health economics.

[135]  D. Buss,et al.  Iodine in British foods and diets , 1994, British Journal of Nutrition.

[136]  B. Dimond The National Patient Safety Agency , 2001 .

[137]  S. Royal,et al.  Interventions in primary care to reduce medication related adverse events and hospital admissions: systematic review and meta-analysis , 2006, Quality and Safety in Health Care.

[138]  P. Mitchell,et al.  Maintenance treatments for bipolar disorders , 2007 .

[139]  World federation of societies of biological psychiatry , 1990, Biological Psychiatry.

[140]  W. Wiersinga,et al.  Diagnosis and management of amiodarone‐induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association , 2004, Clinical endocrinology.

[141]  U. Haustein,et al.  Methotrexate in psoriasis: 26 years’ experience with low‐dose long‐term treatment , 2000, Journal of the European Academy of Dermatology and Venereology : JEADV.

[142]  M. Pirmohamed,et al.  Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.

[143]  W. Wiersinga,et al.  Diagnosis and management of amiodarone‐induced thyrotoxicosis: similarities and differences between North American and European thyroidologists * , 2008, Clinical endocrinology.

[144]  J. Nolan,et al.  Case-finding for unsuspected thyroid disease: costs and health benefits. , 1985, American journal of clinical pathology.

[145]  Tim Straughan,et al.  NHS Information Centre , 2008 .

[146]  N. Devlin,et al.  QA4 IS THE AIM OF THE HEALTH CARE SYSTEM TO MAXIMISE QALYS? AN INVESTIGATION OF ‘WHAT ELSE MATTERS’ IN THE NHS , 2011 .

[147]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance Treatment of Major Depressive Disorder and Treatment of Chronic Depressive Disorders and Subthreshold Depressions , 2002, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[148]  David O. Taylor,et al.  Can patients with COPD or asthma take a beta-blocker , 2010, Cleveland Clinic Journal of Medicine.

[149]  David W Bates,et al.  The Costs Associated With Adverse Drug Events Among Older Adults in the Ambulatory Setting , 2005, Medical care.

[150]  W. Waring,et al.  Pattern of lithium exposure predicts poisoning severity: evaluation of referrals to a regional poisons unit. , 2007, QJM : monthly journal of the Association of Physicians.

[151]  K. Loh Amiodarone-induced thyroid disorders: a clinical review , 2000, Postgraduate medical journal.

[152]  J. Franklyn,et al.  Successful Treatment of Amiodarone-Induced Thyrotoxicosis , 2002, Circulation.

[153]  A. Hoes,et al.  Amiodarone‐induced thyroid dysfunction associated with cumulative dose , 2002, Pharmacoepidemiology and drug safety.

[154]  M. Schott Amiodarone-Induced Thyrotoxicosis Is a Predictor of Adverse Cardiovascular Outcome , 2009 .

[155]  L. Laine,et al.  Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. , 2006 .

[156]  A. B. Prasad,et al.  British National Formulary , 1994 .

[157]  A. Gamma,et al.  Suicide in 406 Mood-Disorder Patients With and Without Long-Term Medication: A 40 to 44 Years' Follow-Up , 2005, Archives of suicide research : official journal of the International Academy for Suicide Research.

[158]  J. Karnon,et al.  Model-based cost-effectiveness analysis of interventions aimed at preventing medication error at hospital admission (medicines reconciliation). , 2009, Journal of evaluation in clinical practice.

[159]  P. Macdonald,et al.  Tolerability of carvedilol in patients with heart failure and concomitant chronic obstructive pulmonary disease or asthma. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[160]  J. Thorp,et al.  Effects of oxprenolol on the airways of normal and bronchitic subjects , 1976, European Journal of Clinical Pharmacology.

[161]  A. Egberts,et al.  Adverse drug events in hospitalized patients A comparison of doctors, nurses and patients as sources of reports , 1999, European Journal of Clinical Pharmacology.

[162]  James M Robins,et al.  Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study , 2002, The Lancet.

[163]  E. Salpeter,et al.  Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. , 2002, Annals of internal medicine.

[164]  L. Niskanen,et al.  Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial , 1999, The Lancet.

[165]  K. Jamison,et al.  Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. , 2004, The American journal of psychiatry.

[166]  J. Chanard,et al.  Long-term follow-up of acute renal failure caused by angiotensin converting enzyme inhibitors. , 1998, American journal of hypertension.

[167]  J. Kellum,et al.  Acute kidney injury: epidemiology and diagnostic criteria , 2006, Current opinion in critical care.

[168]  Arl Medford,et al.  British Thoracic Society , 2004 .

[169]  Silas Martin,et al.  Patient-based utilities for bipolar disorder-related health states. , 2005, Journal of affective disorders.

[170]  Julia A. Kelleher,et al.  Improving laboratory monitoring at initiation of drug therapy in ambulatory care: a randomized trial. , 2005, Archives of internal medicine.

[171]  J. Avorn,et al.  Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD) , 1999, American heart journal.

[172]  D A Revicki,et al.  Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications. , 1998, Journal of affective disorders.

[173]  L. Kohn,et al.  To Err Is Human : Building a Safer Health System , 2007 .

[174]  B. Pitt ACE Inhibitors in Heart Failure: Prospects and Limitations , 1997, Cardiovascular Drugs and Therapy.

[175]  R. Fleming Equity and Excellence: liberating the NHS , 2010 .

[176]  S. Cantor,et al.  Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. , 2001, Surgery.

[177]  J. E. Hansen,et al.  beta-Adrenergic blockade with pindolol (LB-46) in mild to moderate asthma. , 1981, Chest.

[178]  S. Yusuf,et al.  Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure , 1995 .

[179]  M. Johannesson,et al.  Patients' willingness to pay for autologous blood donation. , 1997, Health policy.

[180]  M. Sculpher,et al.  Decision Modelling for Health Economic Evaluation , 2006 .

[181]  R. Tallis,et al.  PRESCRIPTION OF CONTRAINDICATED AND INTERACTING DRUGS IN ELDERLY PATIENTS ADMITTED TO HOSPITAL , 1984, The Lancet.

[182]  Rainu Kaushal,et al.  Technology Evaluation: Return on Investment for a Computerized Physician Order Entry System , 2006, J. Am. Medical Informatics Assoc..

[183]  R. Califf,et al.  Economic effects of beta-blocker therapy in patients with heart failure. , 2004, The American journal of medicine.

[184]  M. Weinstein,et al.  What Do Patients Value?: Willingness to Pay for Ultrasound in Normal Pregnancy , 1985, Medical care.

[185]  B. Lipworth,et al.  Think the impossible: beta-blockers for treating asthma. , 2009, Clinical science.

[186]  B. Psaty,et al.  Cardiovascular risk factors and incident acute renal failure in older adults: the cardiovascular health study. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[187]  L. Laine,et al.  Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. , 2006, The American journal of medicine.

[188]  E. Salpeter,et al.  Cardioselective -Blockers in Patients with Reactive Airway Disease , 2002, Annals of Internal Medicine.

[189]  James Nguyen,et al.  Incidence and predictors of 30-day readmission among patients hospitalized for advanced liver disease. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[190]  L. Curtis,et al.  Unit Costs of Health and Social Care 2016 , 2015 .

[191]  A. Gray Adverse events and the National Health Service: an economic perspective , 2003 .

[192]  S. Palmer,et al.  Cost-utility of a disease management program for patients with asthma , 2007, International Journal of Technology Assessment in Health Care.

[193]  F. Bogazzi,et al.  Glucocorticoids are preferable to thionamides as first-line treatment for amiodarone-induced thyrotoxicosis due to destructive thyroiditis: a matched retrospective cohort study. , 2009, The Journal of clinical endocrinology and metabolism.

[194]  A. Waldo Thyroid Function Abnormalities during Amiodarone Therapy for Persistent Atrial Fibrillation , 2008 .

[195]  D. Au Use of β blockers in patients with COPD , 2008, Thorax.

[196]  Robert J Volk,et al.  Psychological benefits of prostate cancer screening: the role of reassurance , 2002, Health expectations : an international journal of public participation in health care and health policy.

[197]  J. Saurat,et al.  Impact of adalimumab treatment on health‐related quality of life and other patient‐reported outcomes: results from a 16‐week randomized controlled trial in patients with moderate to severe plaque psoriasis , 2007, The British journal of dermatology.

[198]  S. Hernández-Díaz,et al.  Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. , 2000, Archives of internal medicine.

[199]  P J Schneider,et al.  Cost of medication-related problems at a university hospital. , 1995, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[200]  Elisabeth Fenwick,et al.  A guide to cost-effectiveness acceptability curves. , 2005, The British journal of psychiatry : the journal of mental science.

[201]  T A Brennan,et al.  The Institute of Medicine report on medical errors--could it do harm? , 2000, The New England journal of medicine.

[202]  B J O'Brien,et al.  Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods , 2002, Statistical methods in medical research.

[203]  M. Iseman,et al.  The effect of topical ophthalmic instillation of timolol and betaxolol on lung function in asthmatic subjects. , 1986, The American review of respiratory disease.